Lee and colleagues suggested that the overexpressed IL-13 may induce goblet cell hyperplasia, mucus hypersecretion and negatively correlated with the forced expiratory volume in 1 s (FEV1) of COPD patients36–38 and a 24-week treatment study of Lebrikizumab, which is a humanized anti-IL-13 mAb, for decline in frequency of COPD exacerbations and lung function is ongoing (NCT02546700). This evidence concerns the gene IL13 and chronic obstructive pulmonary disease.